



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** November 12, 2010

**To:** NCCTG Primary Clinical Research Associates

**From:** Jack Beranek  
Research Protocol Specialist

**Re:** N0572, A Phase I/II Trial of Sorafenib and CCI-779 in Patients with  
Recurrent Glioblastoma

Changes in the above study for specimen collection and shipment have occurred. NCI has discontinued the Translational Research Initiative (TRI). As a result, Biopathology Center (BPC) in Columbus, OH will no longer supply kits for this study nor will they accept specimens being shipped to BPC effective immediately. Recruitment will not be interrupted because of this. If you need study kits, have specimens to be shipped, or have questions about putting patients on to the study, please call Roxann Neumann at 507/538-0602 or email Roxann at [neumann.roxann@mayo.edu](mailto:neumann.roxann@mayo.edu) for clarification on what to do with specimens. A protocol addendum will be forthcoming with updated information on kits and new shipment information.

If you have any questions, please feel free to contact me.

Enclosure